ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GDTC vs TPST // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

CytoMed Therapeutics Limited (NASDAQ) VS. Tempest Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GDTC 1 — TPST 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GDTC VS. TPST) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GDTC TPST SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 2/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.6 34.7 +14.90 GDTC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $10.7M $10.7M -$8.8K TPST /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GDTC REV TPST REV GDTC GROSS % TPST GROSS % GDTC FCF TPST FCF
FY 2025 — $0 — — — -$26.8M
FY 2024 — $0 — — — -$33.5M
FY 2023 — $0 — — — -$27.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GDTC // BETA —
TPST // BETA —